⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 15, 2025Open Access

Supplementary Figure S3 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition

Qi Ye Bohan Ma Lei Li Zixi Wang Mingming Lu Jialu Kang Yuzeshi Lei Shan Xu Ke Wang Yanlin Jian Yizeng Fan Bin Wang Jing Liu Yang Gao Jian Ma Lei Li

View Full Paper

Ask AI

Bookmark

Share

Key Points

BPD effectively induces BRCA2 degradation, enhancing sensitivity to PARP inhibition in cancer cells.
The figure clearly illustrates the mechanism of action in metastatic castration-resistant prostate cancer.
Analysis involved the examination of BPD's capacity to degrade BRCA2, showcasing its therapeutic potential.
Findings suggest that targeting BRCA2 with PROTACs could improve treatment outcomes for aggressive prostate cancers.

Implication

Supplementary analysis shows that peptide-based degradation of BRCA2 enhances PARP inhibition in prostate cancer.

Abstract

Supplementary Fig. S3. BPD effectively induces BRCA2 degradation. Related to Fig. 2.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ye et al. (2025) studied this question.

synapsesocial.com/papers/68d46ccf31b076d99fa68fba https://doi.org/10.1158/0008-5472.30125752

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S4 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
2Supplementary Figure S7 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
3Supplementary Figure S5 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
4Supplementary Figure S2 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
5Supplementary Figure S1 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025